Lower Reimbursement, Lack of PBM Reform “Starting to Cripple” Community Oncology - from @obrtweets @kirollospharmd

ow.ly/o59O50Rtwyn

In February 2023, the FDA announced a shortage of carboplatin and cisplatin. These shortages have negatively impacted every disease state, including gynecologic and genitourinary cancer. #gyncsm | DrDanaChase Kirollos Hanna

ow.ly/L4BS50Pn5Qx

Amazing presentation from Katy Rezvani, M.D., Ph.D showing for the first time impressive early activity with Cd70 targeting CAR-NK cells in Hodgkin lymphoma in a basket trial for hematologic malignancies with solid tumor trial starting. The EBMT ASTCT #EBMT2023

Amazing!

#GDUOP2022 starts Wednesday! My fellow co-chairs and I have put together an agenda that can’t be missed. Join us tomorrow for 3 days of exciting debates and critical updates.

Register for FREE or upgrade to on-demand: okt.to/HsPdha

#oncopharmacy #oncologypharmacy

Want to learn more about #GDUOP2022 ? Here what the co-chairs have to say about this years event and what you can expect. Registration is free! Listen to the podcast: okt.to/tZpmPk

#oncologypharmacy #Clinicalpathwayslearningnetwork Oncology Learning Network Kirollos Hanna

Happy Easter! Easter, or Pascha, is the oldest and most important Christian feast, celebrating the Resurrection of Jesus Christ on the third day after his crucifixion, as described in the New Testament.

Some pharmacists sit on an imaginary pedestal. There is no justification to disrespect a colleague because you're a PharmD vs BSPharm. Even if you're a fellow of this and fellow of that, we're all Rphs at the end of the day.

Join Thomasina Morris, RPh, MHA, BCOP, Judith A Smith, RPh, MHA, BCOP, and Kirollos Hanna, PharmD, BCPS, BCOP, for an April 12 candid conversation on personalizing patient care with #PARPi for pharmacists at 7:00 PM EDT bit.ly/20Ovarian22 #MedEd

About time. #TwitteRx and #oncopharm welcome Kirollos Hanna to the Twitter world 🌎 he knows all things 🩸 🧬 related. Only took an in-person #HOPAAC22 to convince him how cool we are 🤓